<div id="readability-page-1"><p>Marex Group plc purchased a new stake in shares of  Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor  purchased 3,817,780 shares of the company's stock, valued at approximately $10,423,000. Marex Group plc owned approximately 1.61% of Sana Biotechnology at the end of the most recent quarter.</p><ul><li>There May Still Be Time to Get in on These 3 Trending Biotechs</li></ul><p>A number of other hedge funds have also bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in  Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company's stock valued at $3,101,000 after acquiring an additional 824,505 shares during the period.  Captrust Financial Advisors grew its position in shares of  Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company's stock valued at $43,000 after purchasing an additional 4,807 shares in the last quarter.  BNP Paribas Financial Markets raised its stake in shares of  Sana Biotechnology by 46.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company's stock valued at $42,000 after purchasing an additional 4,931 shares during the period.  Brevan Howard Capital Management LP lifted its holdings in  Sana Biotechnology by 85.3% during the 2nd quarter. Brevan Howard Capital Management LP now owns 260,723 shares of the company's stock worth $712,000 after purchasing an additional 120,016 shares in the last quarter.  Finally, Adage Capital Partners GP L.L.C. bought a new position in  Sana Biotechnology in the 2nd quarter worth about $1,916,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors. </p><div><p><span></span><span>Get <strong>Sana Biotechnology</strong> alerts:</span></p></div><h2>Sana Biotechnology Price Performance</h2><p>SANA stock opened at $5.14 on Friday. The firm has a 50 day simple moving average of $4.50 and a two-hundred day simple moving average of $3.76. The stock has a market cap of $1.37 billion, a PE ratio of -5.30 and a beta of 1.95. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $7.30. </p><p>Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.03.  On average, research analysts expect that  Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts have recently weighed in on the company. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Sana Biotechnology in a research report on Monday, December 8th. Citizens Jmp boosted their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a &#34;market outperform&#34; rating in a research note on Thursday, October 30th. Wall Street Zen cut shares of Sana Biotechnology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 22nd. Wedbush raised their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, November 7th. Finally, HC Wainwright decreased their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the stock. According to data from MarketBeat, the company  has an average rating of &#34;Moderate Buy&#34; and an average price target of $8.33.</p><p><b>Check Out Our Latest Research Report on Sana Biotechnology</b></p><h2>Sana Biotechnology Profile</h2> (Free Report)<p>Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Sana Biotechnology</li><li>Using the MarketBeat Dividend Yield Calculator</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>Where Do I Find 52-Week Highs and Lows?</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0FOQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sana Biotechnology Right Now?</h2><p>Before you consider Sana Biotechnology, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.</p><p>While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SANA

<p>Marex Group plc purchased a new stake in Sana Biotechnology, Inc. worth $10.42 million during the second quarter, acquiring 3,817,780 shares. This investment represents approximately 1.61% ownership in Sana Biotechnology. Other hedge funds also increased their positions in the company. Sana Biotechnology's stock opened at $5.14 on Friday, with a market cap of $1.37 billion. Analysts have mixed ratings on the stock, with an average rating of 'Moderate Buy' and an average price target of $8.33.</p>

Marex Group plc Takes $10.42 Million Position in Sana Biotechnology, Inc. $SANA